HAT1 antibody
![Research Use Only](static/images/certificates/ruo.jpg)
GTX110643
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetHAT1
Overview
- SupplierGeneTex
- Product NameHAT1 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:5000-1:20000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.98 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Gene ID8520
- Target nameHAT1
- Target descriptionhistone acetyltransferase 1
- Target synonymshistone acetyltransferase type B catalytic subunit; KAT1
- HostRabbit
- IsotypeIgG
- Protein IDO14929
- Protein NameHistone acetyltransferase type B catalytic subunit
- Scientific DescriptionHistone acetylation, particularly of histone H4, plays an important role in replication-dependent chromatin assembly. This gene encodes a histone acetylase that contains A, B, and D motifs, present in many N-acetyltransferases, including those that acetylate substrates other than histones. Alternatively spliced transcript variants that encode different isoforms have been identified for this gene. [provided by RefSeq]
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Epigenetic modifications of tumor necrosis factor-alpha in joint cartilage tissue from osteoarthritis patients - CONSORT. Zhang Q et al., 2021 Dec 23, Medicine (Baltimore)Read more
- Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1. Lin CY et al., 2020 Aug, J Mol Med (Berl)Read more